ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2147

Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study

Filipe Pinheiro1, Rui Gaspar2, Bruno Fernandes3, Armando Peixoto2, Guilherme Macedo2 and Iva Brito4, 1Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 2Gastroenterology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 3Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 4Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal

Meeting: ACR Convergence 2022

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), Drug toxicity, rheumatoid arthritis, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster III: PsA

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Methotrexate is an immunomodulatory agentu sed in several inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or inflammatory bowel disease (IBD). Despite being previously associated with the development of liver damage, recent studies have showed significant less hepatotoxicity. The aim of our study was to evaluate the prevalence and development of liver injury in methotrexate-treated patients with inflammatory diseases.

Methods: We performed a cross-sectional study where consecutive patients followed at the Rheumatology and Gastroenterology Departments of a tertiary center, diagnosed with RA, SpA or IBD, treated with methotrexate, were submitted to liver elastography and liver function tests. Clinical and laboratory data were collected, including duration of treatment and cumulative dose of methotrexate. The cutoff for significant fibrosis was ≥7.1 kPa. Comparisons between groups (significant versus non-significant fibrosis) was evaluated using chi-square, t test and Mann-Whitney U test. Spearman’s correlation was used to assess associations between two or more continuous variables. Logistic regression was performed to determine predictors of significant fibrosis.

Results: A total of 101 patients were included, 60 (59.4%) females, aged 46.2±12.6 years at the start of methotrexate. Forty-nine patients (48.5%) had RA, 17 (16.8%) SpA and 35 (34.7%) IBD, and 35 (34.7%) consumed alcohol daily. Patients were exposed to methotrexate for a median of 204 (72-146) weeks, with a median cumulative dose of 2385 (940-5200) mg. Eleven patients (10.9%) had significant fibrosis, with a median score of 4.8 (4.1-5.9) kPa.

Patients with significant fibrosis had higher rates of daily alcohol consumption (63.6% vs 31.1%, p=0.045), but there were no differences in methotrexate’s exposure time or cumulative dose. There was a very significant correlation between exposure time to methotrexate and cumulative dose (Spearman’s rho 0.904, p< 0.001), but no correlations were found between cumulative dose and elastography scores. Methotrexate exposure time (OR 1.001, 95% CI 0.999-1.003, p=0.549) and cumulative dose (OR 1.000, 95% CI 1000-1000, p=0.629) were shown not to be predictors of significant fibrosis, unlike alcohol (OR 3.875, 95%CI 1.049-014319, p=0.042). In multivariate logistic regression analysis, methotrexate cumulative and exposure times were not predictors of significant fibrosis, even when adjusted for alcohol consumption.

Another analysis was performed with the division of groups at the median – ≤4.8kPa (n=55) and >4.8 kPa (n=46). Methotrexate exposure time (OR 1.000, 95% CI 0.999-1.002, p=0.607) and cumulative dose (OR 1.000, 95% CI 1.000-1.000, p=0.376) were also shown not to be predictors of fibrosis in patients on methotrexate.

Conclusion: In this study, we found that fibrosis detected on hepatic elastography was not associated with the cumulative dose or time of exposure to methotrexate, unlike alcohol. Therefore, it is of paramount importance to redefine risk factors for liver toxicity In patients with inflammatory diseases under treatment with methotrexate.


Disclosures: F. Pinheiro, None; R. Gaspar, None; B. Fernandes, None; A. Peixoto, None; G. Macedo, None; I. Brito, None.

To cite this abstract in AMA style:

Pinheiro F, Gaspar R, Fernandes B, Peixoto A, Macedo G, Brito I. Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/cumulative-dose-and-exposure-time-to-methotrexate-were-not-shown-to-be-predictors-of-hepatic-fibrosis-by-elastography-a-monocentric-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cumulative-dose-and-exposure-time-to-methotrexate-were-not-shown-to-be-predictors-of-hepatic-fibrosis-by-elastography-a-monocentric-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology